(Press-News.org) In cases where standard therapies fail, a medication called XEN1101 reduces seizure frequency by more than 50% in some patients and sometimes eliminates them altogether, a new study shows. Unlike several treatments that must be started at low doses and slowly ramped up, the new drug can safety be taken at its most effective dose from the start, the authors say.
Focal seizures, the most common type seen in epilepsy, occur when nerve cells in a particular brain region send out a sudden, excessive burst of electrical signals. Along with seizures, this uncontrolled activity can lead to abnormal behavior, periods of lost awareness, and mood changes. While many available therapies control or reduce seizures, they fail to stop seizures in about one-third of patients and may cause harsh side effects, experts say.
Led by researchers at NYU Grossman School of Medicine, a new clinical trial found that patients who added XEN1101 to their current antiseizure treatments saw a 33% to 53% drop in monthly seizures, depending on their dose. By contrast, those given a placebo had on average 18% fewer seizures during the treatment phase of the trial, which lasted eight weeks. Most patients then volunteered to extend the trial, with about 18% of those treated with the new drug remaining entirely seizure free after six months, and about 11% having no seizures after a year or longer.
“Our findings show that XEN1101 may offer a swift, safe, and effective way to treat focal epilepsy,” said study lead author, neurologist Jacqueline French, MD. “These promising results offer hope for those who have struggled for decades to get their symptoms under control.”
French, a professor in the Department of Neurology at NYU Langone Health, notes that XEN1101 was well tolerated by the study participants, who reported side effects similar to other antiseizure treatments, including dizziness, nausea, and fatigue, and the majority felt well enough to continue the regimen. Another benefit of the drug, she adds, is that it takes more than a week to break down, so levels in the brain remain consistent over time. This steadiness allows the treatment to be started at full strength and helps to avoid dramatic spikes that worsen side effects, and dips that allow seizures to return. This lengthy breakdown time also allows for a “grace period” if a dose is accidently skipped or taken late.
XEN1101 is part of a class of chemicals called potassium-channel openers, which avert seizures by boosting the flow of potassium out of nerves, stopping them from firing. French notes that while other drugs of this kind have been explored for epilepsy patients in the past, such treatments were taken out of use because the compounds were later found to gradually build up in the skin and eyes, prompting safety concerns, the researchers say.
Meanwhile, XEN1101 combines the effectiveness of potassium-channel openers with the safety of more traditional drugs, says French, who is also a member of NYU Langone’s Comprehensive Epilepsy Center. A report on the trial is publishing Oct. 9 in the journal JAMA Neurology.
For the study, which included 285 men and women with epilepsy and ran from January 2019 to September 2021, the research team recruited adults with epilepsy who had already tried and stopped taking an average of six drugs that failed to treat their focal seizures. Patients in the trial had to have experienced at least four episodes a month despite ongoing treatment to qualify. The patients were randomly provided either a daily oral capsule of XEN1101 (in doses of 10 milligrams, 20 milligrams, or 25 milligrams) or an inert placebo tablet that appeared identical to the real drug.
Among the results, the trial revealed no signs of dangerous side effects such as heart problems, allergic reactions, or concerning skin discolorations. However, French says that the research team plans to expand the number of patients exposed to the drug and monitor for potential issues that could arise in the long term, or include specific groups of people, such as pregnant women. In addition, the team also intends to explore XEN1101 for other types of seizures, including those that broadly affect the brain at the same time (generalized seizures).
“Our study highlights the importance of finding as many therapeutic options as possible for those who suffer from seizures,” says French. “Since everyone responds differently, treating epilepsy cannot be a one-size-fits-all approach.”
Funding for the study was provided by Xenon Pharmaceuticals Inc., a biotechnology company based in Vancouver, Canada, that develops therapies for neurological disorders, including epilepsy and major depressive disorder. Xenon Pharmaceuticals is the maker of XEN1101.
French has served as a consultant for Xenon Pharmaceuticals Inc. and has received past research and travel support from the company. She has also similarly received support from groups not involved in the study, including the Epilepsy Foundation, Aeonian/Aeovian; Alterity Therapeutics; Anavex; Angelini Pharma; Arkin Holdings; Arvelle Therapeutics; Athenen Therapeutics/Carnot Pharma; Autifony Therapeutics; Baergic Bio; Beacon Biosignals; Biogen; Biohaven Pharmaceuticals; BioMarin Pharmaceutical; BioXcel Therapeutics; Bloom Science; BridgeBio Pharma; CAMP Therapeutics; Cerebral Therapeutics; Cerevel Therapeutics; Clinical Education Alliance; Coda Biotherapeutics; Corlieve Therapeutics; Crossject; Eisai; Eliem Therapeutics; Encoded Therapeutics; Engage Therapeutics; Engrail; Epalex; Epihunter; Epiminder; Epitel; the Epilepsy Study Consortium, the Epilepsy Foundation, Equilibre BioPharmaceuticals; Greenwich Biosciences; GRIN Therapeutics; GW Pharmaceuticals; Janssen Pharmaceutica; Jazz Pharmaceuticals; Knopp Biosciences; Korro Bio; Lipocine; LivaNova; Longboard Pharmaceuticals; Lundbeck; Marinus Pharmaceuticals; Mend Neuroscience; Merck; NeuCyte; Neumirna Therapeutics; Neurocrine Biosciences; Neuroelectrics USA Corp.; Neuronetics; NeuroPace; NxGen MDx; Ono Pharmaceutical; Otsuka Pharmaceutical Development; Ovid Therapeutics; Paladin Labs; Passage Bio; Pfizer; Praxis Precision Medicines; PureTech Health; Rafa Laboratories; Receptor Holdings; SK Life Science; Sofinnova; Stoke Therapeutics; Supernus; Synergia Medical; Takeda Pharmaceuticals; Third Rock Ventures; UCB; Ventus Therapeutics; Xeris Biopharma Holdings; Zogenix; and Zynerba. The terms and conditions of all of these relationships are being managed by NYU Langone Health.
In addition to French, other investigators involved in the study are Roger Porter MD, at the University of Pennsylvania in Philadelphia; Emilio Perucca, MD, PhD, at the University of Melbourne in Australia; Martin Brodie, MD, at the University of Glasgow in Scotland; Michael Rogawski, MD, PhD, at the University of California, Davis, in Sacramento; and Simon Pimstone, MD, PhD; Ernesto Aycardi, MD; Cynthia Harden, MD; Jenny Qian, MS; Constanza Luzon Rosenblut, MD; Christopher Kenney, MD; and Gregory Beatch, PhD, at Xenon Pharmaceuticals.
Media Inquiries:
Shira Polan
Phone: 212-404-4279
shira.polan@nyulangone.org
END
New drug offers relief for treatment-resistant epilepsy patients
2023-10-09
ELSE PRESS RELEASES FROM THIS DATE:
Capturing immunotherapy response in a blood drop
2023-10-09
*EMBARGOED UNTIL 11 A.M. MONDAY, OCT. 9*
Liquid biopsies are blood tests that can serially measure circulating tumor DNA (cell-free DNA that is shed into the bloodstream by dying cancer cells). When used in patients with advanced non-small cell lung cancer undergoing immunotherapy, they may identify patients who could benefit from treatment with additional drugs, according to a phase 2 clinical trial in the U.S. and Canada. The trial is led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel ...
Soccer goalies process the world differently, muti-sensory integration tests show
2023-10-09
In the game of soccer (association football), goalkeepers have a unique role. To do the job well, they must be ready to make split-second decisions based on incomplete information to stop their opponents from scoring a goal. Now researchers reporting in Current Biology on October 9 have some of the first solid scientific evidence that goalkeepers show fundamental differences in the way they perceive the world and process multi-sensory information.
“Unlike other football players, goalkeepers are required to make thousands of very fast decisions based on limited or incomplete sensory information,” says Michael Quinn, the study’s ...
Depressive symptoms and mortality among adults
2023-10-09
About The Study: This study of 23,000 individuals found a higher risk of all-cause, cardiovascular disease, and ischemic heart disease mortality among adults with moderate to severe depressive symptoms compared to those without depressive symptoms. Public health efforts to improve awareness and treatment of depression and associated risk factors could support a comprehensive, nationwide strategy to reduce the burden of depression.
Authors: Zefeng Zhang, M.D., Ph.D., of the Centers for Disease Control and Prevention in Atlanta, is the corresponding author.
To access the embargoed study: ...
Estimates of major depressive disorder and treatment among adolescents by race and ethnicity
2023-10-09
About The Study: During the first full calendar year of the pandemic, approximately 1 in 5 adolescents had major depressive disorder, and less than half of adolescents who needed treatment had any mental health treatment, according to this analysis of nationally representative survey data of 10,000 U.S. adolescents. Adolescents in racial and ethnic minority groups, particularly Latinx, experienced the lowest treatment rates.
Authors: Michael William Flores, Ph.D., M.P.H., of the Cambridge Health Alliance in Cambridge, Massachusetts, is the corresponding author.
To access ...
Cancer drug restores immune system’s ability to fight tumors
2023-10-09
A new, bio-inspired drug restores the effectiveness of immune cells in fighting cancer, a team led by researchers at The University of Texas at Austin has found. In mouse models of melanoma, bladder cancer, leukemia and colon cancer, the drug slows the growth of tumors, extends lifespan and boosts the efficacy of immunotherapy. The research is published in the journal Cancer Cell and could be a game changer for many cancer patients.
Many cancers delete a stretch of DNA called 9p21, which is the most common deletion across all cancers, occurring in 25%-50% of certain cancers such as melanoma, bladder ...
Newfound mechanism suggests drug combination could starve pancreatic cancer
2023-10-09
A new combination of treatments safely decreased growth of pancreatic cancer in mice by preventing cancer cells from scavenging for fuel, a new study finds.
Led by researchers at NYU Grossman School of Medicine, its Department of Radiation Oncology, and the Perlmutter Cancer Center, the work builds on prior discoveries at NYU Langone that revealed how pancreatic cancer cells, to avert starvation and keep growing, find alternate fuel sources. Normally supplied by the bloodstream, oxygen, blood sugar, and other resources become scarce as the increasing density of fast-growing pancreatic tumors cuts off their own blood supply. ...
Epigenetic regulator MOF drives mitochondrial metabolism
2023-10-09
The intricate control of cellular metabolism relies on the coordinated and harmonious interplay between the nucleus and mitochondria. On the one hand, mitochondria are the hub for the production of essential metabolites, which aside from being required to meet the energy demands of the cell, also serve as the building blocks for constructing both genetic and epigenetic landscapes in the nucleus. On the other hand, the majority of mitochondrial metabolic enzymes are encoded by the nuclear genome, making the function of these two organelles highly interdependent on one another. Inter-organellar communication is aided by molecules that shuttle between these two compartments. ...
Do you know a stroke hero?
2023-10-09
Each year, approximately 800,000 people in the U.S. experience a stroke, according to the American Heart Association’s 2023 Heart Disease and Stroke Statistical Update. Individuals and groups making a difference in the stroke community have a chance to be nationally recognized with a 2024 Stroke Hero Award from the American Stroke Association, a division of the American Heart Association, which is devoted to a world of healthier lives for all.
Stroke is the fifth leading cause of death and a leading cause of serious, long-term ...
UofL receives $16 million to increase supply of primary care physicians for underserved rural and urban areas
2023-10-09
The University of Louisville has received $16 million to help increase Kentuckians’ access to health care, particularly in underserved rural and urban areas. The UofL School of Medicine will use the funds from a four-year grant from the Health Resources and Services Administration (HRSA) to train more primary care physicians and encourage them to practice in underserved communities where they are needed.
Kentucky has a severe shortage of health care providers, with at least some portion of 113 of the state’s 120 counties designated as Health Professional Shortage Areas, including ...
TAVR: Less than one-third of patients enter cardiac rehab after heart procedure
2023-10-09
The vast majority of people who have a minimally invasive heart valve replacement procedure do not participate in recommended cardiac rehabilitation, a Michigan Medicine-led study finds.
Researchers used clinical registry and health care claims data from over 3,300 patients who underwent transcatheter aortic valve replacement, or TAVR, in Michigan across 24 hospitals between 2016 and mid-2020, to determine the rate of cardiac rehabilitation participation and the factors associated with its utilization.
Results published in JACC: Advances reveal that just 30.6% ...